Role of constitutively activated and insulin-like growth factor-stimulated ERK1/2 signaling in human hepatoma cell proliferation and apoptosis: Evidence for heterogeneity of tumor cell lines

Annals of the New York Academy of Sciences

Volumn 1030, Issue , 2004, Pages 219-229

  Alexia, Catherine ^a   Lasfer, Malika ^a   Groyer, André ^a  

^a INSERM   (France)

Author keywords

Apoptosis; Human hepatoma cell lines; Insulin like growth factors; MAP kinase (ERK) signaling; Proliferation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CISPLATIN; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR;

APOPTOSIS; AUTOCRINE EFFECT; CELL PROLIFERATION; CELL PROTECTION; CELL STRAIN HEPG2; CONFERENCE PAPER; CONTROLLED STUDY; DNA REPLICATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PARACRINE SIGNALING; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 15044341000     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1329.028     Document Type: Conference Paper

References (53)

1. PITOT, H.C. 1998. Hepatocyte death in hepatocarcinogenesis. Hepatology 28: 1-5.
2. THORGEIRSSON, S.S., T. TERAMOTO & V.M. FACTOR. 1998. Dysregulation of apoptosis in hepatocellular carcinoma. Semin. Liver Dis. 18: 115-122.
3. MACDONALD, G.A. 2001. Pathogenesis of hepatocellular carcinoma. Clin. Liver Dis. 5: 69-85.
4. FAUSTO, N., A.D. LAIRD & E.M. WEBBER. 1995. Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J. 9: 1527-1536.
5. MICHALOPOULOS, G.K. & M.C. DEFRANCES. 1997. Liver regeneration. Science 276: 60-66.
6. DAUGHADAY, W.H. & P. ROTWEIN. 1989. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 10: 68-91.
7. HUMBEL, R.E. 1990. Insulin-like growth factors I and II. Eur. J. Biochem. 190: 445-462.
8. PIETRZKOWSKI, Z., G. MULHOLLAND, L. GOMELLA, et al. 1993. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53: 1102-1106.
9. COOLICAN, S.A., D.S. SAMUEL, D.Z. EWTON, et al. 1997. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J. Biol. Chem. 272: 6653-6662.
10. SCRIMGEOUR, A.G., V.A. BLAKESLEY, B.S. STANNARD & D. LEROITH. 1997. Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis. Endocrinology 138: 2552-2558.
11. BASERGA, R. 1994. Oncogenes and the strategy of growth factors. Cell 79: 927-930.
12. KALEKO, M., W.J. RUTTER & A.D. MILLER. 1990. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell. Biol. 10: 464-473.
13. SELL, C., M. RUBINI, R. RUBIN, et al. 1993. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. USA 90: 11217-11221.
14. RESNICOFF, M., D. COPPOLA, C. SELL, et al. 1994. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 54: 4848-4850.
15. RESNICOFF, M., C. SELL, M. RUBINI, et al. 1994. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 54: 2218-2222.
16. MACAULAY, V.M. 1992. Insulin-like growth factors and cancer. Br. J. Cancer 65: 311-320.
17. KHANDWALA, H.M., I.E. MCCUTCHEON, A. FLYVBJERG, K.E. FRIEND. 2000. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21: 215-244.
18. SELL, C., R. BASERGA & R. RUBIN. 1995. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res. 55: 303-306.
19. RESNICOFF, M., D. ABRAHAM, W. YUTANAWIBOONCHAI, et al. 1995. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 55: 2463-2469.
20. LEROITH, D., H. WERNER, D. BEITNER-JOHNSON & C.T. ROBERTS, JR. 1995. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 16: 143-163.
21. RUBIN, R. & R. BASERGA. 1995. Insulin-like growth factor-I receptor: its role in cell proliferation, apoptosis, and tumorigenicity. Lab. Invest. 73: 311-331.
22. CARO, J.F., J. POULOS, O. ITTOOP, et al. 1988. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J. Clin. Invest. 81: 976-981.
23. CARIANI, E., C. LASSERRE, D. SEURIN, et al. 1988. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 48: 6844-6849.
24. PARK, B.C., M.H. HUH & J.H. SEO. 1995. Differential expression of transforming growth factor α and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma. J. Hepatol. 22: 286-294.
25. NARDONE, G., M. ROMANO, A. CALABRO, et al. 1996. Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology 23: 1304-1312.
26. SCHARF, J.G., G. RAMADORI & F. DOMBROWSKI. 2000. Analysis of the IGF axis in pre-neoplastic hepatic foci and hepatocellular neoplasms developing after low-number pancreatic islet transplantation into the livers of streptozotocin diabetic rats. Lab. Invest. 80: 1399-1411.
27. SCHIRMACHER, P., W.A. HELD, D. YANG, et al. 1992. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res. 52: 2549-2556.
28. LIU, P., O. TERRADILLOS, C.A. RENARD, et al. 1997. Hepatocarcinogenesis in woodchuck hepatitis virus/c-myc mice: sustained cell proliferation and biphasic activation of insulin-like growth factor II. Hepatology 25: 874-883.
29. SU, Q., Y.F. LIU, J.F. ZHANG, et al. 1994. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology 20: 788-799.
30. KIM, S.O., J.G. PARK & Y.I. LEE. 1996. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res. 56: 3831-3836.
31. TAO, X., D. SHEN, H. REN, et al. 2000. Hepatitis B virus X protein activates expression of IGF-IR and VEGF in hepatocellular carcinoma cells. Zhonghua Gan Zang Bing Za Zhi 8: 161-163.
32. PRICE, J.A., S.J. KOVACH, T. JOHNSON, et al. 2002. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology 36: 1089-1097.
33. NISHIYAMA, M. & J.R. WANDS. 1992. Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 183: 280-285.
34. TANAKA, S., L. MOHR, E.V. SCHMIDT, et al. 1997. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 26: 598-604.
35. WHITMARSH, A.J. & R.J. DAVIS. 1996. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74: 589-607.
36. SU, B. & M. KARIN. 1996. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr. Opin. Immunol. 8: 402-411.
37. TREISMAN, R. 1996. Regulation of transcription by MAP kinase cascades. Curr. Opin. Cell Biol. 8: 205-215.
38. BRENNER, B., U. KOPPENHOEFER, C. WEINSTOCK, et al. 1997. Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J. Biol. Chem. 272: 22173-22181.
39. DAVIS, R.J. 1999. Signal transduction by the c-Jun N-terminal kinase. Biochem. Soc. Symp. 64: 1-12.
40. JOHNSON, G.L. & R.R. VAILLANCOURT. 1994. Sequential protein kinase reactions controlling cell growth and differentiation. Curr. Opin. Cell Biol. 6: 230-238.
41. LEROITH, D., H. WERNER, D. BEITNER-JOHNSON & C.T. ROBERTS, JR. 1995. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 16: 143-163.
42. 2: role in cell survival following oxidant injury. J. Biol. Chem. 271: 4138-4142.
43. WANG, X., J.L. MARTINDALE, Y. LIU & N.J. HOLBROOK. 1998. The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem. J. 333(Part 2): 291-300.
44. HE, H., X. WANG, M. GOROSPE., et al. 1999. Phorbol ester-induced mononuclear cell differentiation is blocked by the mitogen-activated protein kinase kinase (MEK) inhibitor PD98059. Cell Growth Differ. 10: 307-315.
45. HAYAKAWA, J., M. OHMICHI, H. KURACHI, et al. 1999. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem. 274: 31648-31654.
46. PERSONS, D.L., E.M. YAZLOVITSKAYA, W. CUI & J.C. PELLING. 1999. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res. 5: 1007-1014.
47. GAO, X.S., J. ASSAUMI, S. KAWASAKI, et al. 1995. Sensitivity of anticancer drugs in NIH3T3′ cells transfected with oncogenes accompanied by pSV2neo vector. Anti-cancer Res. 15: 1911-1914.
48. FOKSTUEN, T., Y.B. RABO, J.N. ZHOU, et al. 1997. The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line. Anti-cancer Res. 17: 2347-2352.
49. WANG, X., J.L. MARTINDALE & N.J. HOLBROOK. 2000. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275: 39435-39443.
50. HUYNH, H., T.T. NGUYEN, K.H. CHOW, et al. 2003. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 3: 19.
51. BUENDIA, M.A. 2000. Genetics of hepatocellular carcinoma. Semin. Cancer Biol. 10: 185-200.
52. MITSUI, H., N. TAKUWA, T. MARUYAMA, et al. 2001. The MEK1-ERK MAP kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int. J. Cancer 92: 55-62.
53. MIKULA, M, J. GOTZMANN, A.N. FISCHER, et al. 2003. The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis. Oncogene 22: 6725-6738.